Patent application number | Description | Published |
20100095350 | UNIVERSALLY USABLE HUMAN-INTERACTION PROOF - Disclosed is a system and method for generating a universally usable, completely automated public turing test to tell a computer and a human apart (CAPTCHA). The universally usable CAPTCHA uses contextually related pictures and sounds to present concepts to a user. The pictures allow the CAPTCHA to be used by someone who could see, and the audio would allow the CAPTCHA to be used by someone who could not see. This combination of sound and images should make the CAPTCHA more universally usable for a larger population of users than previously known CAPTCHAs. | 04-15-2010 |
20120144455 | AUDIO BASED HUMAN-INTERACTION PROOF - A method and system for allowing access to computer functions such as websites that utilizes a user's ability to recognize sounds is described. The method presents a user a series of sounds. Some of the sounds presented in the series are labeled as validation sounds. The user is asked to provide an input every time he or she hears the validation sound. The user must identify the sound within a specified length of time. The system disclosed comprises a user interface, a sound database module, a generation module, and a sound database module. The generation module creates the validation test file and expected answer. The answer confirmation module checks the input from the requesting computer and provides access to the computer function if the computer input from the requesting computer meets the required parameters. | 06-07-2012 |
20140181921 | AUDIO BASED HUMAN-INTERACTION PROOF - A method and system for allowing access to computer functions such as websites that utilizes a user's ability to recognize sounds is described. The method presents a user a series of sounds. Some of the sounds presented in the series are labeled as validation sounds. The user is asked to provide an input every time he or she hears the validation sound. The user must identify the sound within a specified length of time. The system disclosed comprises a user interface, a sound database module, a generation module, and a sound database module. The generation module creates the validation test file and expected answer. The answer confirmation module checks the input from the requesting computer and provides access to the computer function if the computer input from the requesting computer meets the required parameters. | 06-26-2014 |
Patent application number | Description | Published |
20110269130 | Antibiotice Susceptibility Profiling Methods - The invention provides methods for the rapid determination of the antibiotic susceptibility of a microorganism, such as, an infectious microorganism in a biological sample, using fluorescence in situ hybridization (“FISH”). Methods of the invention may be applied to the rapid identification, typing, antibiotic susceptibility determination, and/or antibiotic minimum inhibitory concentration (MIC) determination for any infectious microorganism, such as a Gram positive bacteria, a Gram negative bacteria, or a yeast. | 11-03-2011 |
20130089886 | METHOD FOR DIRECT AND RAPID IDENTIFICATION OF MICROORGANISMS AND ANTIMICROBIAL SUSCEPTIBILITY TESTING FROM POSITIVE BLOOD CULTURES - Methods of the invention include the isolation of intact, viable microorganism(s) from positive blood culture (“PBC”) samples for use in downstream analyses such as identification and antimicrobial susceptibility testing (“AST”). The methods involve collecting a portion of the PBC sample, adding a choline-containing solution, lysing the blood cells, isolating the viable microorganism, and performing downstream analysis of the isolated, viable microorganism. The methods can be applied to a variety of gram-positive bacteria, gram-negative bacteria, and/or yeast, and particularly to strains of | 04-11-2013 |
Patent application number | Description | Published |
20140044714 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF - Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject. | 02-13-2014 |
20150274836 | MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY - Described herein is the use of phage display antibody engineering technology and synthetic peptide screening to identify SD1 and SD2, human single-domain antibodies to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539-588) of human mesothelin close to the cell surface. SD2 binds full-length mesothelin. To investigate SD1 as a potential therapeutic agent, a recombinant human Fc (SD1-hFc) fusion protein was generated. The SD1-hFc protein exhibits strong complement-dependent cytotoxicity (CDC), in addition to antibody-dependent cellular cytotoxicity (ADCC), against mesothelin-expressing tumor cells. Furthermore, the SD1-hFc protein causes significant tumor growth inhibition of tumor xenografts in nude mice. SD1 and SD2 are the first human single-domain antibodies targeting mesothelin-expressing tumors. | 10-01-2015 |
Patent application number | Description | Published |
20080200391 | Human Extracellular Matrix-1 - A human ECM-1 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for stimulating the differentiation in growth of osteoblasts and osteoclasts, which may be used to promote the healing of bone fractures and de novo bone formation, for osteoporosis, for and to promote angiogenesis. Antagonists to the polypeptide of the present invention are also disclosed which may be utilized to treat osteodystrophy, osteohypertrophy, osteoma, osteoblastoma and cancers. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention. | 08-21-2008 |
20090005301 | 207 Human Secreted Proteins - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 01-01-2009 |
20090011983 | 186 Human Secreted Proteins - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 01-08-2009 |
20090029914 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 01-29-2009 |
20120122762 | 186 Human Secreted Proteins - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 05-17-2012 |
20160015789 | FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN - A stable liquid pharmaceutical composition comprising an albumin-human growth hormone (hGH) fusion protein whose amino acid sequence is set forth as SEQ ID NO: 1 and a buffer, wherein the stable liquid pharmaceutical composition has a pH range of 5.5-6.5. | 01-21-2016 |
Patent application number | Description | Published |
20110008358 | HUMAN MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND IGF-II - Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (K | 01-13-2011 |
20110020361 | HUMAN ANTI-MESOTHELIN MONOCLONAL ANTIBODIES - Disclosed herein are isolated human monoclonal antibodies that specifically bind human mesothelin with a binding affinity of about 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human mesothelin in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed. | 01-27-2011 |
20130156781 | ANTI-DR4 AGONIST ANTIBODIES - The present invention provides antibodies and antibody fragments that specifically recognize and agonize the death receptor 4 (DR4). Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors. | 06-20-2013 |
20130177570 | ANTI-HUMAN FOLATE RECEPTOR BETA ANTIBODIES AND METHODS OF USE - Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ. | 07-11-2013 |
20140271646 | MONOSPECIFIC AND BISPECIFIC HUMAN MONOCLONAL ANTIBODIES TARGETING INSULIN-LIKE GROWTH FACTOR II (IGF-II) - Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed. | 09-18-2014 |
20150110798 | ANTI-HUMAN FOLATE RECEPTOR BETA ANTIBODIES AND METHODS OF USE - Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FRβ. | 04-23-2015 |